Experts on the haematological therapy market have stated that we are currently seeing rapid innovation.
The business intelligence provider GBI Research has produced a report on this area, released last week, covering therapy for sickle cell disease, paroxysmal nocturnal haemoglobinuria, anaemia, thalassemia and hereditary hemochromatosis.
It is 'experiencing a significant level of first-in-class innovation, with 92 of its 327 pipeline programs with a disclosed molecular target identified as first-in-class', the experts write.
At present, this market is small and has a substantial lack of funding and unmet need, especially those patients with more severe disease. Hence there is large scope for investment in drug development, which could lead to major clinical breakthroughs. Overall, the authors at GBI Research believe a successful first-in-class product could gain a large market share.
Author Callum Dew says: 'Although blood transfusions can manage certain red blood cell disorders, this approach itself can lead to iron overload. Similarly, bone marrow transplants, which can treat a range of haematological disorders, carry many risks, ranging from anaemia to more severe and potentially fatal disorders.
'There are a multitude of reasons for investing in the haematological disorders market. Aside from the small number of effective marketed products within the therapy area, there are also a wide range of indications which vary greatly in their prevalence and a number of orphan diseases.
'Globally prevalent disorders such as anaemias, of which the most common form - iron deficiency anaemia - is estimated to affect over 13% of the world's population, also represent significant investment opportunities due to the number of patients eligible for treatment.'
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.